ITIF hosted a panel discussion with leading experts on innovation policy, technology transfer, and business, who spoke to the practical implications of exercising federal “march-in” rights and why it would be a grave and ill-timed mistake for the U.S. health, competitiveness, and research landscape.

ITIF hosted an expert panel discussion about the report and the vital role IP has played throughout the pandemic.

ITIF hosted an expert panel discussion exploring the groundbreaking innovations and policy considerations impacting the field of multi-cancer early detection.

ITIF and the Bayh-Dole Coalition hosted a joint video webinar that will clarify the provision’s intent and explain once and for all how Bayh-Dole’s march-in right can and cannot be used.

ITIF hosted a discussion on this critical issue. The event featured a keynote address by Simon Tripp of TEConomy Partners, author of the new report “Response and Resilience: Lessons Learned from Global Life Sciences Ecosystems in the COVID-19 Pandemic,” followed by an expert panel of respondents.

The bill fails to recognize three critical realities: 1) that drug prices are, in fact, not a significant driver of raging inflation; 2) that there exist better mechanisms to reform Medicare Part D drug pricing practices; 3) that mandated government price controls do inflict serious harm on nations’ life-sciences innovation systems.

Congress should ignore pressure from progressive activists who want to use drug price controls to move to a government-led drug discovery and production system and instead focus on more pragmatic reforms.

The WTO’s approval of a TRIPS waiver for IP related to COVID-19 vaccines is essentially a shotgun blast completely missing the broadside of a barn.

The United States uniquely leads the world in innovating new drugs and getting them to patients first while sustaining a globally competitive industry and over time making drugs affordable by incentivizing competition and creating generic pathways.

ITIF’s Center for Life Sciences Innovation advocates for accelerating biopharmaceutical innovation by recognizing that the public and private sectors both have essential roles to play in advancing the technology, economic, and policy factors that underpin it.

America’s world-leading life-sciences innovation system is a product of myriad policies, but one that is all too often overlooked is the Bayh-Dole Act, which gives IP rights to universities that produce innovation with federally funded R&D.

Capitol Hill is awash in proposals to stem allegedly out-of-control drug prices, but in their zealousness to rein in drug prices, policymakers risk imperiling drug innovation to the detriment of patients and the economy. The better way to produce more medical cures at lower cost over the long haul will be to double down on innovation, not deter it.